Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) and Takeda Pharmaceutical (NYSE:TAK – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Profitability
This table compares Amphastar Pharmaceuticals and Takeda Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amphastar Pharmaceuticals | 13.27% | 15.31% | 7.15% |
| Takeda Pharmaceutical | 8.26% | 11.51% | 5.59% |
Valuation & Earnings
This table compares Amphastar Pharmaceuticals and Takeda Pharmaceutical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amphastar Pharmaceuticals | $719.89 million | 1.67 | $98.09 million | $2.19 | 12.90 |
| Takeda Pharmaceutical | $4,693.24 billion | 0.01 | -$1.01 billion | $0.76 | 28.63 |
Amphastar Pharmaceuticals has higher earnings, but lower revenue than Takeda Pharmaceutical. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Amphastar Pharmaceuticals and Takeda Pharmaceutical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amphastar Pharmaceuticals | 1 | 7 | 0 | 0 | 1.88 |
| Takeda Pharmaceutical | 0 | 1 | 2 | 1 | 3.00 |
Amphastar Pharmaceuticals presently has a consensus target price of $23.33, indicating a potential downside of 17.40%. Given Amphastar Pharmaceuticals’ higher possible upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Takeda Pharmaceutical.
Insider & Institutional Ownership
65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Amphastar Pharmaceuticals has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.
Summary
Amphastar Pharmaceuticals beats Takeda Pharmaceutical on 10 of the 15 factors compared between the two stocks.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients. The company’s products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
